Compare Recursion Pharmaceuticals Inc (RXRX) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Workiva Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B), while Workiva Inc trades at $72.75 (market cap $4.01B). The key difference: Workiva Inc is far larger — about 2.2× Recursion Pharmaceuticals Inc's market cap, and Workiva Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | WK | |
|---|---|---|
Market Cap | $1.86B | $4.01B |
Sector | Health | Technology |
52-Week High | $6.79 | $93.31 |
52-Week Low | $2.84 | $44.31 |
Enterprise Value | $1.38B | $3.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Workiva (WK) trades at $73.71, down 3.71% today, showing technical support near $72 with bullish moving averages. The company demonstrates strong revenue growth, with 2026 revenue reaching $966 million and net income turning positive at $47 million. Recent earnings beats and high analyst buy ratings (89%) support optimism, though elevated valuation ratios (P/E 87.75) warrant caution.
Outlook remains positive with consistent earnings beats and AI product launches driving growth. Key risks include high valuation multiples and competitive pressures in the SaaS sector. The consensus price target of $82.50 suggests 12% upside potential from current levels, supported by institutional accumulation and strong operational cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
